CRDF logo

CRDFCardiff Oncology Inc

$1.50
$0.05
(3.23%)
Today
Closed $1.50
$0.00
(0.00%)
After Hours
Updated: 04:37 PM EDT
Reported EarningsMay 14
Mkt Cap$102.55M
Vol2.82M
News
all
press releases
This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.read more...
Benzinga
News Placeholder
More News
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Moderate Buy" by Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has ass...
MarketBeat
News Placeholder
Cardiff Oncology (NASDAQ:CRDF) Trading Down 1.1% - Here's What Happened
Cardiff Oncology (NASDAQ:CRDF) Stock Price Down 1.1% - Here's Why...
MarketBeat
News Placeholder
Noble Financial Issues Optimistic Estimate for CRDF Earnings
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Research analysts at Noble Financial raised their Q1 2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a note issued to...
MarketBeat
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat...
MarketBeat
News Placeholder
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar
Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company's investigational PLK1 inhibitor onvansertib during a webinar focused...
MarketBeat
News Placeholder
What is Zacks Research's Forecast for CRDF FY2027 Earnings?
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Investment analysts at Zacks Research lowered their FY2027 EPS estimates for Cardiff Oncology in a note issued to investors on Monday, March 2nd...
MarketBeat
News Placeholder
Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Cardiff Oncology from a "sell" rating to a "hold" rating in a research note on Wednesday...
MarketBeat
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One research analyst...
MarketBeat
News Placeholder
HC Wainwright Issues Optimistic Outlook for CRDF Earnings
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Cardiff Oncology in a note issued to investors on Wednesday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.